CAIX was chosen as a target to our CAR because this enzyme is overexpressed in many hypoxic solid tumors [14, 15], being the most well-characterized tumor-associated antigen overexpressed in ccRCC [16, 17]. Here, CA9 is linked to nonpapillary renal cell carcinoma.